DCI administration decreased FBS, improved glucose intolerance through PI3K/AKT pathway, namely by upregulating insulin receptor substrate (IRS) and PI3Kp85 as well as IRS‐2 and AKT phosphorylation (Cheng et al., 2019). The gene discussed is AKT1; the disease is Glucose intolerance.